問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Surgery

Division of Gastroenterological Surgery

Digestive System Department

更新時間：2023-09-19

詹昆明Chan, Kun-Ming
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

詹昆明

List

34Cases

2017-11-01 - 2021-05-20

Phase III

Completed
A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    unresectable HCC

  • Test Drug

    Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2020-12-15 - 2026-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-11-30 - 2026-09-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
9Sites

Recruiting9Sites

2011-01-01 - 2017-12-31

Phase III

A prospective, randomized, double-blind, placebo-controlled, parallel-group, international multicenter phase III trail of PI-88 in the adjuvant treatment of subjects with hepatitis virus related hepatocellular

  • Condition/Disease

    Postoperative adjuvant therapy for hepatitis virus-related liver cancer

  • Test Drug

    PI-88 or matching placebo

Participate Sites
9Sites

Terminated9Sites

2017-12-01 - 2018-12-20

Others

A Retrospective Chart Review Study of Patients Who Previously Participated in the PATRON Phase III Trial

  • Condition/Disease

    Adjuvant treatment of Post- Resection Hepatocellular Carcinoma

  • Test Drug

    Muparfostat (PI-88)

Participate Sites
10Sites

Terminated8Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

Division of Others-

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

  • Condition/Disease

    advanced stage hepatocellular carcinoma

  • Test Drug

    Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2019-08-01 - 2024-10-30

Phase II

A Phase II Randomized Placebo Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    HBV

  • Test Drug

    YIV-906

Participate Sites
7Sites

Recruiting7Sites

2018-03-01 - 2021-01-04

Phase II

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

  • Condition/Disease

    Previously Treated Unresectable Hepatocellular Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2008-09-01 - 2015-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB